Funding Opportunities

• Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21 Clinical Trial Optional)
  (PA-18-347)
  National Institute of Nursing Research
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)
  (PA-18-348)
  National Institute of Nursing Research
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Self-Management for Health in Chronic Conditions (R01 Clinical Trial Optional)
  (PA-18-376)
  National Institute of Nursing Research
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Community Partnerships to Advance Research (CPAR) (R01 Clinical Trial Optional)
  (PA-18-377)
  National Institute of Nursing Research
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Community Partnerships to Advance Research (CPAR) (R21 Clinical Trial Optional)
  (PA-18-381)
  National Institute of Nursing Research
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Self-Management for Health in Chronic Conditions (R21 Clinical Trial Optional)
  (PA-18-384)
  National Institute of Nursing Research
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Innovative Questions in Symptom Science and Genomics (R15 Clinical Trial Not Allowed)
  (PA-18-471)
  National Institute of Nursing Research
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Personalized Strategies to Manage Symptoms of Chronic Illness (R15 Clinical Trial Not Allowed)
  (PA-18-472)
  National Institute of Nursing Research
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R15 Clinical Trial Not Allowed)
  (PA-18-473)
  National Institute of Nursing Research
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Self-Management for Health in Chronic Conditions (R15 Clinical Trial Not Allowed)
  (PA-18-474)
  National Institute of Nursing Research
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Community Partnerships to Advance Research (CPAR) (R15 Clinical Trial Not Allowed)
  (PA-18-475)
  National Institute of Nursing Research
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01 - Clinical Trial Optional)
  (PA-18-507)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first due date for this FOA is June 5, 2018 Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21 - Clinical Trial Optional)
  (PA-18-508)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first due date for this FOA is June 16, 2018 Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)
  (PA-18-517)
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of General Medical Sciences
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  National Institute for Occupational Safety and Health
  National Center for Emerging and Zoonotic Infectious Diseases
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): March 5, 2018, by 5:00 PM local time of applicant organization.
• Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR) (R43/R44 Clinical Trial Not Allowed)
  (PA-18-525)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Standard dates apply , by 5:00 PM local time of applicant organization.
• Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed)
  (PA-18-529)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Early-life Factors and Cancer Development Later in Life (R03 - Clinical Trial Not Allowed)
  (PA-18-531)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date
• Early-life Factors and Cancer Development Later in Life (R21 - Clinical Trial Not Allowed)
  (PA-18-532)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01 - Clinical Trial Optional)
  (PA-18-545)
  National Institute on Aging
  National Cancer Institute
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trials Not Allowed)
  (PAR-18-505)
  National Institute of Mental Health
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 - Clinical Trial Optional)
  (PAR-18-506)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional )
  (PAR-18-509)
  National Institute on Drug Abuse
  Application Receipt Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 )
  (PAR-18-510)
  National Institute on Drug Abuse
  Application Receipt Date(s): Standard dates apply ), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01 - Clinical Trial Optional)
  (PAR-18-511)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R43/R44 Clinical Trial Not Allowed)
  (PAR-18-512)
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)
  (PAR-18-513)
  National Institute on Aging
  Application Receipt Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequently, standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R41/R42 Clinical Trial Not Allowed)
  (PAR-18-514)
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Human Cell Biology of Alzheimer's Disease Genetic Variants (R01 - Clinical Trial Not Allowed)
  (PAR-18-516)
  National Institute on Aging
  Application Receipt Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequent due dates for new applications: June 8, 2018; October 9, 2018; February 8, 2019; June 7, 2019; October 7, 2019; February 7, 2020; June 7, 2020; and October 7, 2020, by 5:00 PM local time of the applicant organization. Due dates for resubmission and revision applications: July 9, 2018; November 7, 2018; March 7, 2019; July 7, 2019; November 7, 2019; March 7, 2020; July 7, 2020; and November 7, 2020 , by 5:00 PM local time of applicant organization
• Sensory and motor system changes as predictors of preclinical Alzheimers disease (R01 - Clinical Trial Not Allowed)
  (PAR-18-519)
  National Institute on Aging
  Application Receipt Date(s): New: March 26, 2018; June 6, 2018; October 7, 2018; February 7, 2019; June 7, 2019; October 7, 2019; February 7, 2020; June 8, 2020; and October 8, 2020, by 5:00 PM local time of the applicant organization. Resubmission/Revision: July 7, 2018; November 7, 2018; March 7, 2019; July 8, 2019; November 7, 2019; March 6, 2020; July 7, 2020; and November 6, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)
  (PAR-18-521)
  National Eye Institute
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required)
  (PAR-18-522)
  National Eye Institute
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial Required)
  (PAR-18-523)
  National Eye Institute
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Institutional Training Programs to Advance Translational Research on Alzheimer's Disease and AD Related Dementias (T32 - Clinical Trial Not Allowed)
  (PAR-18-524)
  National Institute on Aging
  Application Receipt Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequently, standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional)
  (PAR-18-527)
  National Institute on Drug Abuse
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NeuroNEXT Clinical Trials (U01 - Clinical Trial Optional)
  (PAR-18-528)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
  (PAR-18-530)
  National Cancer Institute
  National Institute of Dental and Craniofacial Research
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): The first due date for all types of applications allowed for this FOA is March 8, 2018. Thereafter Standard dates apply, by 5:00 PM local time of applicant organization, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trials Optional)
  (PAR-18-533)
  National Institute on Deafness and Other Communication Disorders
  Application Receipt Date(s): June 19, 2018; February 20, 2019; October 18, 2019; June 18, 2020; February 22, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01)
  (PAR-18-534)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 15, 2018; August 17, 2018, February 15, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21 - Clinical Trial Optional)
  (PAR-18-538)
  National Institute on Aging
  Application Receipt Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequent due dates are June 20, 2018; February 20, 2019; June 20, 2019; February 20, 2020; and June 22, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• International Research Scientist Development Award (IRSDA) (K01) - Independent Clinical Trial Not Allowed
  (PAR-18-539)
  John E. Fogarty International Center
  National Cancer Institute
  Application Receipt Date(s): March 7, 2018; March 7, 2019; March 6, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• International Research Scientist Development Award (IRSDA) (K01) - Independent Clinical Trial Required
  (PAR-18-540)
  John E. Fogarty International Center
  National Cancer Institute
  Application Receipt Date(s): March 7, 2018; March 7, 2019; March 6, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) - Clinical Trial Optional
  (PAR-18-541)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): February 7, 2018, August 9, 2018, February 9, 2019, August 9, 2019, February 11, 2020, by 5:00 PM local time of applicant organization.
• NINDS CREATE Bio Development Track: Preclinical Development for Biotechnology Products and Biologics (U01 - Clinical Trial Optional)
  (PAR-18-542)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 20, 2018, July 18, 2018, February 13, 2019, July 18, 2019, February 13, 2020, and July 20, 2020), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• CREATE Bio Development Track: Preclinical and Early-Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional)
  (PAR-18-543)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 20, 2018, July 18, 2018, February 13, 2019, July 18, 2019, February 13, 2020, July 20, 2020), and February 12, 2021 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional)
  (PAR-18-544)
  National Institute on Aging
  Application Receipt Date(s): The first application due date is March 29, 2018, by 5:00 PM local time of the applicant organization. Subsequent due dates are June 8, 2018; February 8, 2019; June 8, 2019; February 7, 2020; and June 8, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates, including new, renewal, resubmission, and revision applications. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3) - Clinical Trial Optional
  (PAR-18-546)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): February 7, 2018, August 9, 2018, February 9, 2019, August 9, 2019, February 11, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) - Clinical Trial Required
  (PAR-18-547)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): New applications - February 23, June 6, and October 4 of 2018; February 6, June 6 and October 8 of 2019; February 6, June 8, and October 6 of 2020; February 9 of 2021, by 5:00 PM local time of applicant organization. Resubmitted and revised applications - July 6 and November 6 of 2018; March 6, July 8 and November 6 of 2019; March 6, July 7 and November 6 of 2020; March 9 of 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 - Clinical Trial Optional)
  (PAR-18-548)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 14, 2018; July 18, 2018; February 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020, by 5:00 PM local time of applicant organization.
• Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 - Clinical Trial Optional)
  (PAR-18-549)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 14, 2018; July 18, 2018; February 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020, by 5:00 PM local time of applicant organization.
• Analytical Validation of Candidate Biomarkers for Neurological Disease (U01 Clinical Trial Optional)
  (PAR-18-550)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 14, 2018; July 18, 2018; February, 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Partnership for Aging and Cancer Research (U01 - Clinical Trial Not Allowed)
  (PAR-18-552)
  National Cancer Institute
  National Institute on Aging
  Application Receipt Date(s): June 8, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimers Disease (R01 - Clinical Trial Not Allowed)
  (RFA-AG-18-022)
  National Institute on Aging
  Application Receipt Date(s): March 28, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Consequences of amyloid protein polymorphisms in Alzheimer's disease (R01 - Clinical Trial Not Allowed)
  (RFA-AG-18-025)
  National Institute on Aging
  Application Receipt Date(s): March 28, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
• Limited Competition: Revision Applications for International Centers of Excellence for Malaria Research (U19 Clinical Trial Optional)
  (RFA-AI-17-044)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 30, 2018 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Improving Implementation of Seek, Test, Treat and Retain Strategies among People Who Inject Drugs in Low to Middle Income Countries (R01-Clinical Trial Required)
  (RFA-DA-18-017)
  National Institute on Drug Abuse
  Application Receipt Date(s): April 13, 2018 and November 15, 2018, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed)
  (RFA-DA-18-023)
  National Institute on Drug Abuse
  Application Receipt Date(s): April 17, 2018 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)
  (RFA-DK-17-017)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 20, 2018and, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 - Clinical Trial Optional)
  (RFA-DK-17-018)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 20, 2018; February 21, 2019; February 21, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Support for Small Business Innovation Research to Develop New Open and Closed-Loop Automated Technologies for Better Type 1 Diabetes Therapy and Monitoring (SBIR) (R43/R44- Clinical Trial Not Allowed)
  (RFA-DK-17-029)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 21, 2018, by 5:00 PM local time of applicant organization.
• Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/44 Clinical Trial Not Allowed)
  (RFA-DK-17-030)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 21, 2018, by 5:00 PM local time of applicant organization.
• Limited Competition: Data Analysis and Coordination Center for the MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01 Clinical Trials Not Allowed)
  (RFA-HL-19-007)
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Cancer Institute
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Human Genome Research Institute
  National Institute of Mental Health
  National Institute of Nursing Research
  National Institute of Neurological Disorders and Stroke
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): May 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
• Limited Competition: Clinical Research Sites for MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01-Clinical Trials Not Allowed)
  (RFA-HL-19-008)
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Cancer Institute
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Human Genome Research Institute
  National Institute of Mental Health
  National Institute of Nursing Research
  National Institute of Neurological Disorders and Stroke
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): May 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
• BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 - Clinical Trial Required)
  (RFA-NS-18-021)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020 , and February 22, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44 Clinical Trial Required)
  (RFA-NS-18-022)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM local time of applicant organization.
• BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 - Clinical Trial Required)
  (RFA-NS-18-023)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020 , and February 22, 2021 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Transformative Technology Development for the Human BioMolecular Atlas Program (UG3/UH3 Clinical Trials Not Allowed)
  (RFA-RM-17-025)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): March 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trials Not Allowed)
  (RFA-RM-17-027)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): March 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Microphysiological Systems Data Center U24 (Clinical Trial Not Allowed)
  (RFA-TR-18-005)
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): March 21, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NextGen Tissue Chip Testing Centers: Validating Microphysiological Systems (U24 Clinical Trial Not Allowed)
  (RFA-TR-18-006)
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): March 21, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Health-professional Education Partnership Initiative (HEPI) (R25 Clinical Trial Not Allowed)
  (RFA-TW-17-001)
  John E. Fogarty International Center
  Application Receipt Date(s): March 28, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.